Related Experiment Video
Updated: Aug 19, 2026
A Syngeneic Pancreatic Cancer Mouse Model to Study the Effects of Irreversible Electroporation
Published on: June 8, 2018
Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?
1Clinical Research & Development - Oncology, Pfizer Global R&D, Sandwich, UK. Raz.Dewji@pfizer.com
Abstract:
CI-1033 (Canertinib dihydrochloride) is an orally available pan-erbB receptor tyrosine kinase inhibitor that, unlike the majority of receptor inhibitors, effectively blocks signal transduction through all four members of the erbB family. In addition, it blocks the highly tumorigenic, constitutively activated variant of erbB-1, EGFRvIII, and inhibits downstream signaling through both the Ras/ MAP kinase, and PI-3 kinase/AKT pathways (Figure 1). CI-1033 is also unique in that it is an irreversible inhibitor; thereby providing prolonged suppression of erbB receptor-mediated signaling. Preclinical data show CI-1033 to be efficacious against a variety of human tumors in mouse xenograft models, including breast carcinomas.
Insights
CI-1033 (Canertinib dihydrochloride) is an irreversible pan-erbB inhibitor blocking all four erbB family members and EGFRvIII. Preclinical studies demonstrate its efficacy in human tumor models, including breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The erbB receptor family plays a crucial role in cell proliferation and survival.
- Aberrant signaling through erbB receptors is implicated in various human cancers.
- Existing receptor inhibitors often fail to target all erbB family members or specific variants like EGFRvIII.
Purpose of the Study:
- To evaluate the efficacy of CI-1033 (Canertinib dihydrochloride), an orally available pan-erbB receptor tyrosine kinase inhibitor.
- To assess CI-1033's ability to block signal transduction through all four erbB family members and the EGFRvIII variant.
- To investigate the downstream signaling inhibition and preclinical efficacy of CI-1033.
Main Methods:
- CI-1033 was characterized as an irreversible pan-erbB inhibitor.
- Its ability to block signal transduction through all four erbB family members and EGFRvIII was assessed.
- Downstream signaling pathways, including Ras/MAP kinase and PI-3 kinase/AKT, were analyzed.
- Preclinical efficacy was evaluated in human tumor xenograft models in mice.
Main Results:
- CI-1033 effectively blocks signal transduction through all four erbB family members.
- It inhibits the highly tumorigenic EGFRvIII variant and downstream Ras/MAP kinase and PI-3 kinase/AKT pathways.
- CI-1033 demonstrates prolonged suppression of erbB receptor-mediated signaling due to its irreversible nature.
- Preclinical data indicate efficacy against various human tumors, including breast carcinomas, in mouse xenograft models.
Conclusions:
- CI-1033 is a potent, irreversible pan-erbB inhibitor with broad-spectrum activity.
- It effectively targets multiple erbB family members and oncogenic variants.
- CI-1033 shows significant preclinical efficacy, positioning it as a promising therapeutic agent for erbB-driven cancers.
